Stereotaxis Q2 Earnings Call Highlights

Second-quarter revenue was $7.7 million , with recurring revenue rising to $6.2 million as catheter sales offset lower system revenue. MAGiC catheter revenue grew sharply, but supply constraints limited shipments.

Stereotaxis reported progress with its growth platforms: Synchrony systems began shipping, while GenesisX secured its first U.S. academic medical center order. Management expects two to five GenesisX installations by year-end 2026.

The company projects recurring revenue of approximately $7 million in Q3 and $8 million in Q4, and is targeting cash-flow profitability in the first half of 2027 , driven primarily by increased catheter adoption.

Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.

Revenue declined from the prior-year quarter because the company did not deliver a robotic system during the period, Chief Financial Officer Kim Peery said. However, revenue increased sequentially from the first quarter, driven by higher catheter sales following the U.S. launch of the MAGiC catheter after first-quarter FDA clearance.

System revenue was $1.5 million, compared with $3 million a year earlier, while recurring revenue rose to $6.2 million from $5.8 million. Recurring revenue included more than $1 million of robotic catheter revenue, Chairman and Chief Executive Officer David Fischel said.

Fischel said robotic catheter revenue grew nearly 300% sequentially from the first quarter and 270% sequentially according to Peery’s financial commentary. The company said approximately a dozen U.S. sites received hospital approval to buy MAGiC and began procedures during the second quarter.

The CEO said early physician feedback on MAGiC had been positive, citing comments that the catheter improved targeting, ablation effectiveness and procedural efficiency. Stereotaxis is working through hospital approvals and launches across its U.S. and European installed base, and Fischel said the company expects the “vast majority” of customers to transition from their historical dependence on Johnson & Johnson catheters to Stereotaxis catheters within the next year.

Sales remain limited by available supply, however. The company has a backlog of catheter orders and is receiving more customer orders than it can supply through contract manufacturer Osypka AG, Fischel said. Management said it is making progress in raising production and establishing redundant supply sources. Stereotaxis expects catheter revenue to increase by approximately $1 million in each of the next couple quarters, with a larger opportunity anticipated in 2027.

In response to an analyst question, Fischel said U.S. disposable revenue per robotic procedure has been consistently in the range of $5,000 to more than $8,000, including the company’s QuikCAS device and MAGiC catheter, with potential additions from mapping or diagnostic catheters.

The company also highlighted progress with Synchrony, its digital surgery platform designed to provide workflow, remote-connectivity and artificial-intelligence capabilities. Synchrony can serve as a control platform for Stereotaxis robots and has a separate potential application in non-robotic operating rooms.

After receiving FDA clearance during the second quarter, Stereotaxis received orders for multiple Synchrony systems from several hospitals and shipped its first systems during the quarter.